William Go MD,PhD, Chief Medical Officer for A2 Bio, will be attending the IASLC 2025 Targeted Therapies of Lung Cancer Meeting held February 19-22 in Huntington Beach, CA. Dr. Go will meet with investigators to share updates on our phase 1 studies, EVEREST-1 (NCT05736731) and EVEREST-2 (NCT06051695), which are actively enrolling patients with recurrent unresectable, locally advanced, or metastatic non-small cell lung cancer. For more information on A2 Bio clinical studies, please visit: https://lnkd.in/ge7KqZ8T #TTLC25 #A2Bio #Tmod #CellTherapy #CART
